Neurology News and Research

Latest Neurology News and Research

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

28 Jun 2010

International child health experts to converge for Excellence in Paediatrics

International child health experts to converge on London for Excellence in Paediatrics. Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

28 Jun 2010

OPQC Scheduled Birth Initiative reduces unnecessary planned late pre-term, near-term deliveries in Ohio

A statewide Ohio program significantly reduced the monthly rate of inappropriately scheduled births before 39 weeks gestation, helping to avoid expensive neonatal intensive care unit admissions and decrease the risk of infant deaths, according to two studies by the Ohio Perinatal Quality Collaborative recently published in the American Journal of Obstetrics & Gynecology.

28 Jun 2010

Hospital for Special Surgery announces receipt of $5M commitment from CA Technologies

Hospital for Special Surgery announced the receipt of a $5 million commitment from CA Technologies, an IT management software and solutions company, at its 27th Annual Tribute Dinner at the Waldorf Astoria on June 21, 2010.

28 Jun 2010

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

The U.S. Department of Defense and the Intrepid Fallen Heroes Fund on June 24 officially dedicated the National Intrepid Center of Excellence, a new 72,000-square-foot medical facility in Bethesda, Md., dedicated to researching, diagnosing and treating traumatic brain injury in U.S. military personnel.

28 Jun 2010

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

The nerve cell-damaging plaque that builds up in the brain with Alzheimer's disease also builds up in the retinas of the eyes - and it shows up there earlier, leading to the prospect that noninvasive optical imaging of the eyes could lead to earlier diagnosis, intervention and monitoring of the disease, according to new research.

25 Jun 2010

PecFent receives Positive Opinion from CHMP for treatment of BTCP

Archimedes Pharma, a leading specialty pharma company, today announced that its lead product, PecFent, has received a Positive Opinion from the Committee for Human Medicinal Products, of the European Medicines Agency. The CHMP is recommending PecFent, an innovative fentanyl nasal spray, be authorised for marketing in European Union countries for the treatment of breakthrough cancer pain - sudden, unpredictable episodes of intense pain that occur despite background pain medication.

25 Jun 2010

JZP-6 to be reviewed at joint meeting for treatment of fibromyalgia

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee will review JZP-6 (sodium oxybate) for the treatment of fibromyalgia at a joint meeting on August 20, 2010.

25 Jun 2010

New technique predicts post-stroke recovery

A team of researchers led by NewYork-Presbyterian Hospital/Columbia University Medical Center has developed a method to predict post-stroke recovery of language by measuring the initial severity of impairment.

25 Jun 2010

Group of tests may help predict falls in people with Parkinson's disease: Study

A group of tests may help predict which people with Parkinson's disease are more likely to fall, according to a study published in the June 23, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

24 Jun 2010

Carvedilol drug may lessen degenerative impact of Alzheimer's disease: Researchers

Researchers at Mount Sinai School of Medicine have found that the drug carvedilol, currently prescribed for the treatment of hypertension, may lessen the degenerative impact of Alzheimer's disease and promote healthy memory functions. The new findings are published in two studies in the current issues of Neurobiology of Aging and the Journal of Alzheimer's Disease.

24 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Sun Pharmaceutical Industries Ltd. announced that together with its affiliates ("Sun Pharma") it has executed a settlement agreement with Orion stipulating a dismissal of the lawsuits filed in the United States against Sun Pharma regarding submission of Abbreviated New Drug Applications (ANDAs) for generic versions of Stalevo® and Comtan® tablets.

22 Jun 2010

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

Ipsen today announced top line results of GuidAge®, the longest (5 years) and largest (2,854 subjects) European study in the prevention of Alzheimer's Dementia (AD). This trial was conducted according to the most stringent international standards. The aim of this study was to assess the efficacy of a 5-year treatment with EGb 761® in the prevention of Alzheimer's Dementia in a population of elderly aged 70 or more, with memory complaint spontaneously expressed to their family physician and who lived at home at the inclusion in the study.

22 Jun 2010

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Forest Laboratories, Inc. and Merz Pharmaceuticals GmbH announced today that NAMENDA XR(TM) (memantine hydrochloride) was approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dementia of the Alzheimer's type. NAMENDA XR is a 28 mg once-daily extended-release formulation of NAMENDA.

22 Jun 2010

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Dyax Corp. and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA, announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other therapeutic indications throughout Europe, North Africa, Middle East and Russia.

21 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Incidental findings in brain imaging can be managed ethically and cost-effectively: UBC researchers

The increasing number of incidental findings in brain imaging can be managed ethically and cost-effectively by screening study participants based on gender, age and family history, according to University of British Columbia researchers.

21 Jun 2010

Valeant, Biovail announce definitive merger agreement

Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.

21 Jun 2010

Neurology News and Research

Latest Neurology News and Research

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

International child health experts to converge for Excellence in Paediatrics

OPQC Scheduled Birth Initiative reduces unnecessary planned late pre-term, near-term deliveries in Ohio

Hospital for Special Surgery announces receipt of $5M commitment from CA Technologies

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

PecFent receives Positive Opinion from CHMP for treatment of BTCP

JZP-6 to be reviewed at joint meeting for treatment of fibromyalgia

New technique predicts post-stroke recovery

Group of tests may help predict falls in people with Parkinson's disease: Study

Carvedilol drug may lessen degenerative impact of Alzheimer's disease: Researchers

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Incidental findings in brain imaging can be managed ethically and cost-effectively: UBC researchers

Valeant, Biovail announce definitive merger agreement

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Neurology News and Research

Latest Neurology News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in